CpG still rocks! Update on an accidental drug

Nucleic Acid Therapeutics

Volumn 22, Issue 2, 2012, Pages 77-89

  Krieg, Arthur M ^a  

^a Translate Bio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1018 ISS; AGATOLIMOD; ANTINEOPLASTIC AGENT; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; PLACEBO; RITUXIMAB; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VACCINE;

ALLERGY; ANTINEOPLASTIC ACTIVITY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ERYTHEMA; FOLLICULAR LYMPHOMA; HUMAN; IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INJECTION SITE PAIN; MELANOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; HUMANS; HYPERSENSITIVITY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; VACCINATION;

EID: 84859489110     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0340     Document Type: Review

References (106)

1. AMPOLLINI, L., SOLTERMANN, A., FELLEY-BOSCO, E., LARDINOIS, D., ARNI, S., SPECK, R.F., WEDER, W., and OPITZ, I. (2009). Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. Eur. J. Cardiothorac. Surg. 35, 457-462.
2. APPAY, V., JANDUS, C., VOELTER, V., REYNARD, S., COUPLAND, S.E., RIMOLDI, D., LIENARD, D., GUILLAUME, P., KRIEG, A.M., CEROTTINI, J.C., et al. (2006A). New generation vaccine induces effective melanoma-specific CD8 + T cells in the circulation but not in the tumor site. J. Immunol. 177, 1670-1678.
3. APPAY, V., SPEISER, D.E., RUFER, N., REYNARD, S., BARBEY, C., CEROTTINI, J.C., LEYVRAZ, S., PINILLA, C., and ROMERO, P. (2006B). Decreased specific CD8 + T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur. J. Immunol. 36, 1805-1814.
4. BAITSCH, L., BAUMGAERTNER, P., DEVEVRE, E., RAGHAV, S.K., LEGAT, A., BARBA, L., WIECKOWSKI, S., BOUZOURENE, H., DEPLANCKE, B., ROMERO, P., et al. (2011). Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350-2360.
5. BALSARI, A., TORTORETO, M., BESUSSO, D., PETRANGOLINI, G., SFONDRINI, L., MAGGI, R., MENARD, S., and PRATESI, G. (2004). Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur. J. Cancer 40, 1275-1281.
6. BAUMGAERTNER, P., JANDUS, C., RIVALS, J.P., DERRE, L., LOVGREN, T., BAITSCH, L., GUILLAUME, P., LUESCHER, I.F., BERTHOD, G., MATTER, M., et al. (2011). Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer doi:10.1002/ijc.26297
7. BOURQUIN, C., SCHREIBER, S., BECK, S., HARTMANN, G., and ENDRES, S. (2006). Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int. J. Cancer 118, 2790-2795.
8. BRICHARD, V.G., and LEJEUNE, D. (2007). GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25, B61-71.
9. BRODY, J.D., AI, W.Z., CZERWINSKI, D.K., TORCHIA, J.A., LEVY, M., ADVANI, R.H., KIM, Y.H., HOPPE, R.T., KNOX, S.J., SHIN, L.K., et al. (2010). In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 28, 4324-4332.
10. BUHTOIAROV, I.N., SONDEL, P.M., WIGGINTON, J.M., BUHTOIAROVA, T.N., YANKE, E.M., MAHVI, D.A., and RAKHMILEVICH, A.L. (2011). Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 132, 226-239.
11. CAMPBELL, J.D., CHO, Y., FOSTER, M.L., KANZLER, H., KACHURA, M.A., LUM, J.A., RATCLIFFE, M.J., SATHE, A., LEISHMAN, A.J., BAHL, A., et al. (2009). CpG-containing immunostimulatory DNA sequences elicit TNF-α-dependent toxicity in rodents but not in humans. J. Clin. Invest. 119, 2564-2576.
12. CARPENTIER, A., LAIGLE-DONADEY, F., ZOHAR, S., CAPELLE, L., BEHIN, A., TIBI, A., MARTIN-DUVERNEUIL, N., SANSON, M., LACOMBLEZ, L., TAILLIBERT, S., et al. (2006). Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro. Oncol. 8, 60-66.
13. CARPENTIER, A., METELLUS, P., URSU, R., ZOHAR, S., LAFITTE, F., BARRIE, M., MENG, Y., RICHARD, M., PARIZOT, C., LAIGLE-DONADEY, F., et al. (2010). Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro. Oncol. 12, 401-408.
14. COOPER, C.L., DAVIS, H.L., ANGEL, J.B., MORRIS, M.L., ELFER, S.M., SEGUIN, I., KRIEG, A.M., and CAMERON, D.W. (2005). CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 19, 1473-1479.
15. COOPER, C.L., DAVIS, H.L., MORRIS, M.L., EFLER, S.M., ADHAMI, M.A., KRIEG, A.M., CAMERON, D.W., and HEATHCOTE, J. (2004A). CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24, 693-701.
16. COOPER, C.L., DAVIS, H.L., MORRIS, M.L., EFLER, S.M., KRIEG, A.M., LI, Y., LAFRAMBOISE, C., AL ADHAMI, M.J., KHALIQ, Y., SEGUIN, I., et al. (2004B). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22, 3136-3143.
17. COWDERY, J.S., CHACE, J.H., YI, A.K., and KRIEG, A.M. (1996). Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156, 4570-4575.
18. CRETICOS, P.S., SCHROEDER, J.T., HAMILTON, R.G., BALCER-WHALEY, S.L., KHATTIGNAVONG, A.P., LINDBLAD, R., LI, H., COFFMAN, R., SEYFERT, V., EIDEN, J.J., et al. (2006). Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. New Engl. J. Med. 355, 1445-1455.
19. CROMPTON, P.D., MIRCETIC, M., WEISS, G., BAUGHMAN, A., HUANG, C.Y., TOPHAM, D.J., TREANOR, J.J., SANZ, I., LEE, F.E., DURBIN, A.P., et al. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol. 182, 3318-3326.
20. DAVIS, H.L., WEERATNA, R., WALDSCHMIDT, T.J., TYGRETT, L., SCHORR, J., and KRIEG, A.M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876.
21. DERRE, L., RIVALS, J.P., JANDUS, C., PASTOR, S., RIMOLDI, D., ROMERO, P., MICHIELIN, O., OLIVE, D., and SPEISER, D.E. (2010). BTLA mediates inhibition of human tumorspecific CD8 + T cells that can be partially reversed by vaccination. J. Clin. Invest. 120, 157-167.
22. DUNCAN, C.J., SHEEHY, S.H., EWER, K.J., DOUGLAS, A.D., COLLINS, K.A., HALSTEAD, F.D., ELIAS, S.C., LILLIE, P.J., RAUSCH, K., AEBIG, J., et al. (2011). Impact on malaria parasite multiplication rates in infected volunteers of the proteinin- adjuvant vaccine AMA1-C1/Alhydrogel +CPG 7909. PloS One 6, e22271.
23. ELLIS, R.D., MARTIN, L.B., SHAFFER, D., LONG, C.A., MIURA, K., FAY, M.P., NARUM, D.L., ZHU, D., MULLEN, G.E., MAHANTY, S., et al. (2010). Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PloS One 5, e8787.
24. ELLIS, R.D., MULLEN, G.E., PIERCE, M., MARTIN, L.B., MIURA, K., FAY, M.P., LONG, C.A., SHAFFER, D., SAUL, A., MILLER, L.H., et al. (2009). A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27, 4104-4109.
25. FOURCADE, J., KUDELA, P., ANDRADE FILHO, P.A., JANJIC, B., LAND, S.R., SANDER, C., KRIEG, A., DONNENBERG, A., SHEN, H., KIRKWOOD, J.M., et al. (2008). Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8 + T cells in melanoma patients. J. Immunother. 31, 781-791.
26. FOURCADE, J., KUDELA, P., SUN, Z., SHEN, H., LAND, S.R., LENZNER, D., GUILLAUME, P., LUESCHER, I.F., SANDER, C., FERRONE, S., et al. (2009). PD-1 is a regulator of NY-ESO-1-specific CD8 + T cell expansion in melanoma patients. J. Immunol. 182, 5240-5249.
27. FOURCADE, J., SUN, Z., BENALLAOUA, M., GUILLAUME, P., LUESCHER, I.F., SANDER, C., KIRKWOOD, J.M., KUCHROO, V., and ZAROUR, H.M. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186.
28. FOURCADE, J., SUN, Z., PAGLIANO, O., GUILLAUME, P., LUESCHER, I.F., SANDER, C., KIRKWOOD, J.M., OLIVE, D., KUCHROO, V., and ZAROUR, H.M. (2012). CD8 + T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. in press
29. FRIEDBERG, J.W., KELLY, J.L., NEUBERG, D., PETERSON, D.R., KUTOK, J.L., SALLOUM, R., BRENN, T., FISHER, D.C., RONAN, E., DALTON, V., et al. (2009). Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Brit. J. Haem. 146, 282-291.
30. FRIEDBERG, J.W., KIM, H., MCCAULEY, M., HESSEL, E.M., SIMS, P., FISHER, D.C., NADLER, L.M., COFFMAN, R.L., and FREEDMAN, A.S. (2005). Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferonalpha/beta-inducible gene expression, without significant toxicity. Blood 105, 489-495.
31. GAJEWSKI, T.F., LOUAHED, J., and BRICHARD, V.G. (2010). Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16, 399-403.
32. GEKELER, V., GIMMNICH, P., HOFMANN, H.P., GREBE, C., ROMMELE, M., LEJA, A., BAUDLER, M., BENIMETSKAYA, L., GONSER, B., PIELES, U., et al. (2006). G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16, 83-93.
33. GURSEL, M., GURSEL, I., MOSTOWSKI, H.S., and KLINMAN, D.M. (2006). CXCL16 influences the nature and specificity of CpG-induced immune activation. J. Immunol. 177, 1575-1580.
34. HALPERIN, S.A., DOBSON, S., MCNEIL, S., LANGLEY, J.M., SMITH, B., MCCALL-SANI, R., LEVITT, D., NEST, G.V., GENNEVOIS, D., and EIDEN, J.J. (2006). Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24, 20-26.
35. HALPERIN, S.A., VAN NEST, G., SMITH, B., ABTAHI, S., WHILEY, H., and EIDEN, J.J. (2003). A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461-2467.
36. HARTMANN, G., BATTIANY, J., POECK, H., WAGNER, M., KERKMANN, M., LUBENOW, N., ROTHENFUSSER, S., and ENDRES, S. (2003). Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633-1641.
37. HEMMI, H., TAKEUCHI, O., KAWAI, T., KAISHO, T., SATO, S., SANJO, H., MATSUMOTO, M., HOSHINO, K., WAGNER, H., TAKEDA, K., et al. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
38. HENRY, S.P., BOLTE, H., AULETTA, C., and KORNBRUST, D.J. (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120, 145-155.
39. HIRSH, V., PAZ-ARES, L., BOYER, M., ROSELL, R., MIDDLETON, G., EBERHARDT, W.E., SZCZESNA, A., REITERER, P., SALEH, M., ARRIETA, O., et al. (2011). Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 2667-2674.
40. HOFMANN, M.A., KORS, C., AUDRING, H., WALDEN, P., STERRY, W., and TREFZER, U. (2008). Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31, 520-527.
41. HONDA, K., OHBA, Y., YANAI, H., NEGISHI, H., MIZUTANI, T., TAKAOKA, A., TAYA, C., and TANIGUCHI, T. (2005). Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035-1040.
42. HOUGHTON, M. (2011). Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239, 99-108.
43. IOANNOU, Y., and ISENBERG, D.A. (2000). Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43, 1431-1442.
44. JENNINGS, G.T., and BACHMANN, M.F. (2008). The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521-536.
45. JOHNSON, E.E., BUHTOIAROV, I.N., BALDESHWILER, M.J., FELDER, M.A., VAN ROOIJEN, N., SONDEL, P.M., and RAKHMILEVICH, A.L. (2011). Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti- CD40 mAb and CpG in mice. J. Immunother. 34, 76-84.
46. KARBACH, J., NEUMANN, A., ATMACA, A., WAHLE, C., BRAND, K., VON BOEHMER, L., KNUTH, A., BENDER, A., RITTER, G., OLD, L.J., et al. (2011). Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17, 861-870.
47. KAWAI, T., and AKIRA, S. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650.
48. KIM, Y.H., GIRARDI, M., DUVIC, M., KUZEL, T., LINK, B.K., PINTER-BROWN, L., and ROOK, A.H. (2010). Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 63, 975-983.
49. KLIMEK, L., WILLERS, J., HAMMANN-HAENNI, A., PFAAR, O., STOCKER, H., MUELLER, P., RENNER, W.A., and BACHMANN, M.F. (2011). Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin. Exp. Allergy 41, 1305-1312.
50. KLINE, J.N., and KRIEG, A.M. (2008). Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 21, 434-439.
51. KLINE, J.N., WALDSCHMIDT, T.J., BUSINGA, T.R., LEMISH, J.E., WEINSTOCK, J.V., THORNE, P.S., and KRIEG, A.M. (1998). Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555-2559.
52. KRIEG, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
53. KRIEG, A.M. (2003). CpG DNA: trigger of sepsis, mediator of protection, or both? Scand. J. Infect. Dis. 35, 653-659.
54. KRIEG, A.M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discovery 5, 471-484.
55. KRIEG, A.M. (2007). Antiinfective applications of toll-like receptor 9 agonists. Proc. Am. Thorac. Soc. 4, 289-294.
56. KRIEG, A.M. (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161-167.
57. KRIEG, A.M., EFLER, S.M., WITTPOTH, M., AL ADHAMI, M.J., and DAVIS, H.L. (2004). Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic Bclass CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27, 460-471.
58. KRIEG, A.M., and VOLLMER, J. (2007). Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 220, 251-269.
59. KRIEG, A.M., YI, A.K., MATSON, S., WALDSCHMIDT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY, G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
60. LEONARD, J.P., LINK, B.K., EMMANOUILIDES, C., GREGORY, S.A., WEISDORF, D., ANDREY, J., HAINSWORTH, J., SPARANO, J.A., TSAI, D.E., HORNING, S., et al. (2007). Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13, 6168-6174.
61. LI, J., SONG, W., CZERWINSKI, D.K., VARGHESE, B., UEMATSU, S., AKIRA, S., KRIEG, A.M., and LEVY, R. (2007). Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179, 2493-2500.
62. LINK, B.K., BALLAS, Z.K., WEISDORF, D., WOOLDRIDGE, J.E., BOSSLER, A.D., SHANNON, M., RASMUSSEN, W.L., KRIEG, A.M., and WEINER, G.J. (2006). Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29, 558-568.
63. MANEGOLD, C., GRAVENOR, D., WOYTOWITZ, D., MEZGER, J., HIRSH, V., ALBERT, G., AL-ADHAMI, M., READETT, D., KRIEG, A.M., and LEICHMAN, C.G. (2008). Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with firstline taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3979-3986.
64. MANEGOLD, C., VAN ZANDWIJK, N., SZCZESNA, A., ZATLOUKAL, P., AU, J.S., BLASINSKA-MORAWIEC, M., SERWATOWSKI, P., KRZAKOWSKI, M., JASSEM, J., TAN, E.H., et al. (2012). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as firstline treatment of advanced non-small-cell lung cancer. Ann. Oncol. 23, 72-77.
65. MARSHALL, J.D., FEARON, K., ABBATE, C., SUBRAMANIAN, S., YEE, P., GREGORIO, J., COFFMAN, R.L., and VAN NEST, G. (2003). Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukocyte Biol. 73, 781-792.
66. MARSHALL, J.D., FEARON, K.L., HIGGINS, D., HESSEL, E.M., KANZLER, H., ABBATE, C., YEE, P., GREGORIO, J., CRUZ, T.D., LIZCANO, J.O., et al. (2005). Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24, 63-72.
67. MASON, K.A., NEAL, R., HUNTER, N., ARIGA, H., ANG, K., and MILAS, L. (2006). CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother. Oncol. 80, 192-198.
68. MCHUTCHISON, J.G., BACON, B.R., GORDON, S.C., LAWITZ, E., SHIFFMAN, M., AFDHAL, N.H., JACOBSON, I.M., MUIR, A., AL-ADHAMI, M., MORRIS, M.L., et al. (2007). Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46, 1341-1349.
69. MOLENKAMP, B.G., SLUIJTER, B.J., VAN LEEUWEN, P.A., SANTEGOETS, S.J., MEIJER, S., WIJNANDS, P.G., HAANEN, J.B., VAN DEN EERTWEGH, A.J., SCHEPER, R.J., and DE GRUIJL, T.D. (2008). Local administration of PF-3512676 CpGB instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin. Cancer Res. 14, 4532-4542.
70. MOLENKAMP, B.G., VAN LEEUWEN, P.A., MEIJER, S., SLUIJTER, B.J., WIJNANDS, P.G., BAARS, A., VAN DEN EERTWEGH, A.J., SCHEPER, R.J., and DE GRUIJL, T.D. (2007). Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 13, 2961-2969.
71. MULLEN, G.E., ELLIS, R.D., MIURA, K., MALKIN, E., NOLAN, C., HAY, M., FAY, M.P., SAUL, A., ZHU, D., RAUSCH, K., et al. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PloS One 3, e2940.
72. PASHENKOV, M., GOESS, G., WAGNER, C., HORMANN, M., JANDL, T., MOSER, A., BRITTEN, C.M., SMOLLE, J., KOLLER, S., MAUCH, C., et al. (2006). Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24, 5716-5724.
73. PETRANGOLINI, G., TORTORETO, M., PEREGO, P., CARENINI, N., DE CESARE, M., BALSARI, A., ZUNINO, F., and PRATESI, G. (2008). Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol. Ther. 7, 596-601.
74. PRATESI, G., PETRANGOLINI, G., TORTORETO, M., ADDIS, A., BELLUCO, S., ROSSINI, A., SELLERI, S., RUMIO, C., MENARD, S., and BALSARI, A. (2005). Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 65, 6388-6393.
75. RAYBURN, E.R.,WANG, W.,ZHANG, R., andWANG.H. (2007). Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int. J. Oncol. 30, 1511-1519.
76. REINIS, M., SIMOVA, J., INDROVA, M., BIEBLOVA, J., and BUBENIK, J. (2007). CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int. J. Oncol. 30, 1247-1251.
77. ROSENBERG, S.A., YANG, J.C., and RESTIFO, N.P. (2004). Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
78. RYNKIEWICZ, D., RATHKOPF, M., SIM, I., WAYTES, A.T., HOPKINS, R.J., GIRI, L., DEMURIA, D., RANSOM, J., QUINN, J., NABORS, G.S., et al. (2011). Marked enhancement of the immune response to BioThrax® (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29, 6313-6320.
79. SAGARA, I., ELLIS, R.D., DICKO, A., NIAMBELE, M.B., KAMATE, B., GUINDO, O., SISSOKO, M.S., FAY, M.P., GUINDO, M.A., KANTE, O., et al. (2009). A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel +CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 27, 7292-7298.
80. SENTI, G., JOHANSEN, P., HAUG, S., BULL, C., GOTTSCHALLER, C., MULLER, P., PFISTER, T., MAURER, P., BACHMANN, M.F., GRAF, N., et al. (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 39, 562-570.
81. SIEGRIST, C.A., PIHLGREN, M., TOUGNE, C., EFLER, S.M., MORRIS, M.L., ALADHAMI, M.J., CAMERON, D.W., COOPER, C.L., HEATHCOTE, J., DAVIS, H.L., et al. (2004). Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615-622.
82. SIMONS, F.E., SHIKISHIMA, Y., VAN NEST, G., EIDEN, J.J., and HAYGLASS, K.T. (2004). Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113, 1144-1151.
83. SLUIJTER, B.J., VAN DEN HOUT, M.F., STAM, A.G., LOUGHEED, S.M., SUHOSKI, M.M., VAN DEN EERTWEGH, A.J., VAN DEN TOL, M.P., VAN LEEUWEN, P.A., MEIJER, S., SCHEPER, R.J., et al. (2010). 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clinical Immunol. 137, 221-233.
84. SOMMARIVA, M., DE CECCO, L., DE CESARE, M., SFONDRINI, L., MENARD, S., MELANI, C., DELIA, D., ZAFFARONI, N., PRATESI, G., UVA, V., et al. (2011). TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res. 71, 6382-6390.
85. SPARWASSER, T., MIETHKE, T., LIPFORD, G., BORSCHERT, K., HACKER, H., HEEG, K., and WAGNER, H. (1997). Bacterial DNA causes septic shock. Nature 386, 336-337.
86. SPEISER, D.E., BAUMGAERTNER, P., BARBEY, C., RUBIOGODOY, V., MOULIN, A., CORTHESY, P., DEVEVRE, E., DIETRICH, P.Y., RIMOLDI, D., LIENARD, D., et al. (2006). A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 177, 1338-1348.
87. SPEISER, D.E., LIENARD, D., RUFER, N., RUBIO-GODOY, V., RIMOLDI, D., LEJEUNE, F., KRIEG, A.M., CEROTTINI, J.C., and ROMERO, P. (2005). Rapid and strong human CD8 + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746.
88. SPEISER, D.E., SCHWARZ, K., BAUMGAERTNER, P., MANOLOVA, V., DEVEVRE, E., STERRY, W., WALDEN, P., ZIPPELIUS, A., CONZETT, K.B., SENTI, G., et al. (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J. Immunother. 33, 848-858.
89. STOETER, D., DE LIGUORI CARINO, N., MARSHALL, E., POSTON, G.J., and WU, A. (2008). Extensive necrosis of visceral melanoma metastases after immunotherapy. World J. Surg. Oncol. 6, 30.
90. TELESHOVA, N., KENNEY, J., JONES, J., MARSHALL, J., VAN NEST, G., DUFOUR, J., BOHM, R., LIFSON, J.D., GETTIE, A., and POPE, M. (2004). CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-g-secreting simian immunodeficiency virus-specific T cells. J. Immunol. 173, 1647-1657.
91. THOMPSON, J.A., KUZEL, T., DRUCKER, B.J., URBA, W.J., and BUKOWSKI, R.M. (2009). Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an openlabel, multicenter phase I/II study. Clin. Genitourin. Cancer 7, E58-65.
92. TIGHE, H., TAKABAYASHI, K., SCHWARTZ, D., MARSDEN, R., BECK, L., CORBEIL, J., RICHMAN, D.D., EIDEN, J.J., JR., SPIEGELBERG, H.L., and RAZ, E. (2000A). Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939-1947.
93. TIGHE, H., TAKABAYASHI, K., SCHWARTZ, D., VAN NEST, G., TUCK, S., EIDEN, J.J., KAGEY-SOBOTKA, A., CRETICOS, P.S., LICHTENSTEIN, L.M., SPIEGELBERG, H.L., et al. (2000B). Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124-134.
94. VICARI, A.P., LUU, R., ZHANG, N., PATEL, S., MAKINEN, S.R., HANSON, D.C., WEERATNA, R.D., and KRIEG, A.M. (2009). Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol. Immunother. 58, 615-628.
95. VICARI, A.P., SCHMALBACH, T., LEKSTROM-HIMES, J., MORRIS, M.L., AL-ADHAMI, M.J., LAFRAMBOISE, C., LEESE, P., KRIEG, A.M., EFLER, S.M., and DAVIS, H.L. (2007). Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir. Ther. 12, 741-751.
96. VOLLMER, J., and KRIEG, A.M. (2009). Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204.
97. VOLLMER, J., WEERATNA, R., PAYETTE, P., JURK, M., SCHETTER, C., LAUCHT, M., WADER, T., TLUK, S., LIU, M., DAVIS, H.L., et al. (2004). Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251-262.
98. WANG, D., LI, Y., YU, D., SONG, S.S., KANDIMALLA, E.R., and AGRAWAL, S. (2004). Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int. J. Oncol. 24, 901-908.
99. WEBER, J.S., ZAROUR, H., REDMAN, B., TREFZER, U., O'DAY, S., VAN DEN EERTWEGH, A.J., MARSHALL, E., and WAGNER, S. (2009). Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115, 3944-3954.
100. WEERATNA, R., COMANITA, L., and DAVIS, H.L. (2003). CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol. Cell Biol. 81, 59-62.
101. WEIGEL, B.J., RODEBERG, D.A., KRIEG, A.M., and BLAZAR, B.R. (2003). CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9, 3105-3114.
102. WILLE-REECE, U., FLYNN, B.J., LORE, K., KOUP, R.A., KEDL, R.M., MATTAPALLIL, J.J., WEISS, W.R., ROEDERER, M., and SEDER, R.A. (2005). HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 102, 15190-15194.
103. WILLE-REECE, U., FLYNN, B.J., LORE, K., KOUP, R.A., MILES, A.P., SAUL, A., KEDL, R.M., MATTAPALLIL, J.J., WEISS, W.R., ROEDERER, M., et al. (2006). Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249-1258.
104. WOOLDRIDGE, J.E., BALLAS, Z., KRIEG, A.M., and WEINER, G.J. (1997). Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89, 2994-2998.
105. YI, A.K., CHANG, M., PECKHAM, D.W., KRIEG, A.M., and ASHMAN, R.F. (1998). CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160, 5898-5906.
106. YI, A.K., YOON, J.G., HONG, S.C., REDFORD, T.W., and KRIEG, A.M. (2001). Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. Int. Immunol. 13, 1391-1404.